APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hepatic Encephalopathy Drugs Market Outlook and Growth Opportunities 2026

20 December 2025196 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hepatic Encephalopathy Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hepatic Encephalopathy Drugs market include Umecrine Cognition, Norgine, Mallinckrodt, Lupin, Kannalife Sciences, Kaleido Biosciences, Ferring Pharmaceuticals, Cosmo Pharmaceuticals and Bausch Health, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatic Encephalopathy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatic Encephalopathy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatic Encephalopathy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatic Encephalopathy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatic Encephalopathy Drugs Segment by Company

Umecrine Cognition

Norgine

Mallinckrodt

Lupin

Kannalife Sciences

Kaleido Biosciences

Ferring Pharmaceuticals

Cosmo Pharmaceuticals

Bausch Health

ASKA Pharmaceutical

Hepatic Encephalopathy Drugs Segment by Type

Injection

Oral

Hepatic Encephalopathy Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Hepatic Encephalopathy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hepatic Encephalopathy Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hepatic Encephalopathy Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatic Encephalopathy Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatic Encephalopathy Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatic Encephalopathy Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatic Encephalopathy Drugs industry.

Chapter 3: Detailed analysis of Hepatic Encephalopathy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hepatic Encephalopathy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hepatic Encephalopathy Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatic Encephalopathy Drugs Industry Trends Table 2. Hepatic Encephalopathy Drugs Industry Drivers Table 3. Hepatic Encephalopathy Drugs Industry Opportunities and Challenges Table 4. Hepatic Encephalopathy Drugs Industry Restraints Table 5. Global Hepatic Encephalopathy Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatic Encephalopathy Drugs Revenue Share by Company (2021-2026) Table 7. Global Hepatic Encephalopathy Drugs Sales Volume by Company (tons) & (2021-2026) Table 8. Global Hepatic Encephalopathy Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Hepatic Encephalopathy Drugs Average Price (US$/kg) of Company (2021-2026) Table 10. Global Hepatic Encephalopathy Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hepatic Encephalopathy Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Hepatic Encephalopathy Drugs Company, Product Type & Application Table 13. Global Hepatic Encephalopathy Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatic Encephalopathy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injection Table 18. Significant Companies of Oral Table 19. Global Hepatic Encephalopathy Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 20. Global Hepatic Encephalopathy Drugs Sales Volume by Type (2021-2026) & (tons) Table 21. Global Hepatic Encephalopathy Drugs Sales Volume by Type (2027-2032) & (tons) Table 22. Global Hepatic Encephalopathy Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Hepatic Encephalopathy Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Hepatic Encephalopathy Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hepatic Encephalopathy Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hepatic Encephalopathy Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hepatic Encephalopathy Drugs Sales Value Share by Type (2021-2026) Table 28. Global Hepatic Encephalopathy Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Pharmacies Table 30. Significant Companies of Online Pharmacies Table 31. Significant Companies of Retail Pharmacies Table 32. Global Hepatic Encephalopathy Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 33. Global Hepatic Encephalopathy Drugs Sales Volume by Application (2021-2026) & (tons) Table 34. Global Hepatic Encephalopathy Drugs Sales Volume by Application (2027-2032) & (tons) Table 35. Global Hepatic Encephalopathy Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Hepatic Encephalopathy Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Hepatic Encephalopathy Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hepatic Encephalopathy Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Hepatic Encephalopathy Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Hepatic Encephalopathy Drugs Sales Value Share by Application (2021-2026) Table 41. Global Hepatic Encephalopathy Drugs Sales Value Share by Application (2027-2032) Table 42. Global Hepatic Encephalopathy Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 43. Global Hepatic Encephalopathy Drugs Sales by Region (2021-2026) & (tons) Table 44. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2021-2026) Table 45. Global Hepatic Encephalopathy Drugs Sales by Region (2027-2032) & (tons) Table 46. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2027-2032) Table 47. Global Hepatic Encephalopathy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Hepatic Encephalopathy Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Hepatic Encephalopathy Drugs Sales Value Share by Region (2021-2026) Table 50. Global Hepatic Encephalopathy Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Hepatic Encephalopathy Drugs Sales Value Share by Region (2027-2032) Table 52. Global Hepatic Encephalopathy Drugs Market Average Price (US$/kg) by Region (2021-2026) Table 53. Global Hepatic Encephalopathy Drugs Market Average Price (US$/kg) by Region (2027-2032) Table 54. Global Hepatic Encephalopathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 55. Global Hepatic Encephalopathy Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 57. Global Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2026) Table 58. Global Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 59. Global Hepatic Encephalopathy Drugs Sales Market Share by Country (2027-2032) Table 60. Global Hepatic Encephalopathy Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Hepatic Encephalopathy Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Hepatic Encephalopathy Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Hepatic Encephalopathy Drugs Sales Value Market Share by Country (2027-2032) Table 64. Umecrine Cognition Company Information Table 65. Umecrine Cognition Business Overview Table 66. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 67. Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio Table 68. Umecrine Cognition Recent Development Table 69. Norgine Company Information Table 70. Norgine Business Overview Table 71. Norgine Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 72. Norgine Hepatic Encephalopathy Drugs Product Portfolio Table 73. Norgine Recent Development Table 74. Mallinckrodt Company Information Table 75. Mallinckrodt Business Overview Table 76. Mallinckrodt Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 77. Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio Table 78. Mallinckrodt Recent Development Table 79. Lupin Company Information Table 80. Lupin Business Overview Table 81. Lupin Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 82. Lupin Hepatic Encephalopathy Drugs Product Portfolio Table 83. Lupin Recent Development Table 84. Kannalife Sciences Company Information Table 85. Kannalife Sciences Business Overview Table 86. Kannalife Sciences Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 87. Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio Table 88. Kannalife Sciences Recent Development Table 89. Kaleido Biosciences Company Information Table 90. Kaleido Biosciences Business Overview Table 91. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 92. Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio Table 93. Kaleido Biosciences Recent Development Table 94. Ferring Pharmaceuticals Company Information Table 95. Ferring Pharmaceuticals Business Overview Table 96. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 97. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio Table 98. Ferring Pharmaceuticals Recent Development Table 99. Cosmo Pharmaceuticals Company Information Table 100. Cosmo Pharmaceuticals Business Overview Table 101. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 102. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio Table 103. Cosmo Pharmaceuticals Recent Development Table 104. Bausch Health Company Information Table 105. Bausch Health Business Overview Table 106. Bausch Health Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 107. Bausch Health Hepatic Encephalopathy Drugs Product Portfolio Table 108. Bausch Health Recent Development Table 109. ASKA Pharmaceutical Company Information Table 110. ASKA Pharmaceutical Business Overview Table 111. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 112. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio Table 113. ASKA Pharmaceutical Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Hepatic Encephalopathy Drugs Distributors List Table 117. Hepatic Encephalopathy Drugs Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy Drugs Product Image Figure 2. Global Hepatic Encephalopathy Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hepatic Encephalopathy Drugs Sales (2021-2032) & (tons) Figure 5. Global Hepatic Encephalopathy Drugs Sales Average Price (US$/kg) & (2021-2032) Figure 6. Global Hepatic Encephalopathy Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injection Image Figure 10. Oral Image Figure 11. Global Hepatic Encephalopathy Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 12. Global Hepatic Encephalopathy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hepatic Encephalopathy Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Hepatic Encephalopathy Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hepatic Encephalopathy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatic Encephalopathy Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Pharmacies Image Figure 18. Online Pharmacies Image Figure 19. Retail Pharmacies Image Figure 20. Global Hepatic Encephalopathy Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 21. Global Hepatic Encephalopathy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Hepatic Encephalopathy Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Hepatic Encephalopathy Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hepatic Encephalopathy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Hepatic Encephalopathy Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Hepatic Encephalopathy Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 27. Global Hepatic Encephalopathy Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Hepatic Encephalopathy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Hepatic Encephalopathy Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Hepatic Encephalopathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Hepatic Encephalopathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Hepatic Encephalopathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Hepatic Encephalopathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Hepatic Encephalopathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Hepatic Encephalopathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Hepatic Encephalopathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Hepatic Encephalopathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Hepatic Encephalopathy Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Hepatic Encephalopathy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Hepatic Encephalopathy Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Hepatic Encephalopathy Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Umecrine Cognition
  • Norgine
  • Mallinckrodt
  • Lupin
  • Kannalife Sciences
  • Kaleido Biosciences
  • Ferring Pharmaceuticals
  • Cosmo Pharmaceuticals
  • Bausch Health
  • ASKA Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatic Encephalopathy Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Hepatic Encephalopathy Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Hepatic Encephalopathy Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hepatic Encephalopathy Drugs Market Dynamics
  1. 2.1 Hepatic Encephalopathy Drugs Industry Trends
  2. 2.2 Hepatic Encephalopathy Drugs Industry Drivers
  3. 2.3 Hepatic Encephalopathy Drugs Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy Drugs Industry Restraints
3 Hepatic Encephalopathy Drugs Market by Company
  1. 3.1 Global Hepatic Encephalopathy Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Hepatic Encephalopathy Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Hepatic Encephalopathy Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Hepatic Encephalopathy Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Hepatic Encephalopathy Drugs Company Ranking (2024-2026)
  6. 3.6 Global Hepatic Encephalopathy Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Hepatic Encephalopathy Drugs Company Product Type and Application
  8. 3.8 Global Hepatic Encephalopathy Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hepatic Encephalopathy Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hepatic Encephalopathy Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hepatic Encephalopathy Drugs Market by Type
  1. 4.1 Hepatic Encephalopathy Drugs Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Oral
  4. 4.2 Global Hepatic Encephalopathy Drugs Sales Volume by Type
  5. 4.2.1 Global Hepatic Encephalopathy Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hepatic Encephalopathy Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hepatic Encephalopathy Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hepatic Encephalopathy Drugs Sales Value by Type
  9. 4.3.1 Global Hepatic Encephalopathy Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hepatic Encephalopathy Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hepatic Encephalopathy Drugs Sales Value Share by Type (2021-2032)
5 Hepatic Encephalopathy Drugs Market by Application
  1. 5.1 Hepatic Encephalopathy Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Hepatic Encephalopathy Drugs Sales Volume by Application
  6. 5.2.1 Global Hepatic Encephalopathy Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatic Encephalopathy Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hepatic Encephalopathy Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hepatic Encephalopathy Drugs Sales Value by Application
  10. 5.3.1 Global Hepatic Encephalopathy Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hepatic Encephalopathy Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hepatic Encephalopathy Drugs Sales Value Share by Application (2021-2032)
6 Hepatic Encephalopathy Drugs Regional Sales and Value Analysis
  1. 6.1 Global Hepatic Encephalopathy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatic Encephalopathy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatic Encephalopathy Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Hepatic Encephalopathy Drugs Sales by Region (2027-2032)
  5. 6.3 Global Hepatic Encephalopathy Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hepatic Encephalopathy Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hepatic Encephalopathy Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hepatic Encephalopathy Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Hepatic Encephalopathy Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hepatic Encephalopathy Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Hepatic Encephalopathy Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hepatic Encephalopathy Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Hepatic Encephalopathy Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hepatic Encephalopathy Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hepatic Encephalopathy Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hepatic Encephalopathy Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Hepatic Encephalopathy Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hepatic Encephalopathy Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hepatic Encephalopathy Drugs Sales Value Share by Country, 2025 VS 2032
7 Hepatic Encephalopathy Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Hepatic Encephalopathy Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatic Encephalopathy Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Hepatic Encephalopathy Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Hepatic Encephalopathy Drugs Sales by Country (2027-2032)
  6. 7.4 Global Hepatic Encephalopathy Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hepatic Encephalopathy Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hepatic Encephalopathy Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hepatic Encephalopathy Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hepatic Encephalopathy Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hepatic Encephalopathy Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Umecrine Cognition
  2. 8.1.1 Umecrine Cognition Company Information
  3. 8.1.2 Umecrine Cognition Business Overview
  4. 8.1.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio
  6. 8.1.5 Umecrine Cognition Recent Developments
  7. 8.2 Norgine
  8. 8.2.1 Norgine Company Information
  9. 8.2.2 Norgine Business Overview
  10. 8.2.3 Norgine Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Norgine Hepatic Encephalopathy Drugs Product Portfolio
  12. 8.2.5 Norgine Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Lupin
  20. 8.4.1 Lupin Company Information
  21. 8.4.2 Lupin Business Overview
  22. 8.4.3 Lupin Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lupin Hepatic Encephalopathy Drugs Product Portfolio
  24. 8.4.5 Lupin Recent Developments
  25. 8.5 Kannalife Sciences
  26. 8.5.1 Kannalife Sciences Company Information
  27. 8.5.2 Kannalife Sciences Business Overview
  28. 8.5.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio
  30. 8.5.5 Kannalife Sciences Recent Developments
  31. 8.6 Kaleido Biosciences
  32. 8.6.1 Kaleido Biosciences Company Information
  33. 8.6.2 Kaleido Biosciences Business Overview
  34. 8.6.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio
  36. 8.6.5 Kaleido Biosciences Recent Developments
  37. 8.7 Ferring Pharmaceuticals
  38. 8.7.1 Ferring Pharmaceuticals Company Information
  39. 8.7.2 Ferring Pharmaceuticals Business Overview
  40. 8.7.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
  42. 8.7.5 Ferring Pharmaceuticals Recent Developments
  43. 8.8 Cosmo Pharmaceuticals
  44. 8.8.1 Cosmo Pharmaceuticals Company Information
  45. 8.8.2 Cosmo Pharmaceuticals Business Overview
  46. 8.8.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
  48. 8.8.5 Cosmo Pharmaceuticals Recent Developments
  49. 8.9 Bausch Health
  50. 8.9.1 Bausch Health Company Information
  51. 8.9.2 Bausch Health Business Overview
  52. 8.9.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bausch Health Hepatic Encephalopathy Drugs Product Portfolio
  54. 8.9.5 Bausch Health Recent Developments
  55. 8.10 ASKA Pharmaceutical
  56. 8.10.1 ASKA Pharmaceutical Company Information
  57. 8.10.2 ASKA Pharmaceutical Business Overview
  58. 8.10.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio
  60. 8.10.5 ASKA Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatic Encephalopathy Drugs Value Chain Analysis
  2. 9.1.1 Hepatic Encephalopathy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatic Encephalopathy Drugs Sales Mode & Process
  6. 9.2 Hepatic Encephalopathy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatic Encephalopathy Drugs Distributors
  9. 9.2.3 Hepatic Encephalopathy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst